NIVELES DE RESISTENCIA A DROGAS ANTITUBERCULOSAS EN PACIENTES CON COINFECCIÓN VIH / TUBERCULOSIS, LIMA, 1998-2001.
Objective: To determine resistance rates to first-line antituberculous drugs in clinical samples from patients co-infected with the human immunodeficiency virus (HIV) and M. tuberculosis (TB) in five hospitals in Lima between 1998-2000. Materials and methods: A descriptive study including samples se...
| Published in: | Revista Peruana de Medicina Experimental y Salud Pública Vol. 23; no. 2; pp. 98 - 104 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Published: |
Instituto Nacional de Salud (Peru)
2006
|
| Subjects: | |
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=lth&AN=24391523&site=ehost-live header: @attributes: shortDbName: lth uiTerm: 24391523 longDbName: MedicLatina uiTag: AN controlInfo: bkinfo: jinfo: jid: 17264634 2WT0 jtl: Revista Peruana de Medicina Experimental y Salud Pública issn: 17264634 maglogo: N pubinfo: dt: 2006 vid: 23 iid: 2 pid: 27380 pub: Instituto Nacional de Salud (Peru) artinfo: ui: 24391523 ppf: 98 ppct: 6 formats: fmt: @attributes: type: P size: 185KB tig: atl: NIVELES DE RESISTENCIA A DROGAS ANTITUBERCULOSAS EN PACIENTES CON COINFECCIÓN VIH / TUBERCULOSIS, LIMA, 1998-2001. aug: au: Asencios S., Luis Vásquez C., Lucy Leo H., Elena Quispe T., Neyda Huaroto V., Luz Cabezas S., César affil: Laboratorio de Referencia Nacional de Micobacterias, Centro Nacional de Salud Pública, Instituto Nacional de Salud. Lima, Perú Hospital Nacional Dos de Mayo. Lima, Perú su: Drug resistance Antitubercular agents Mycobacterium tuberculosis HIV-positive persons Isoniazid Streptomycin Rifampin Patients Peru sug: subj: Peru Drug resistance Antitubercular agents Mycobacterium tuberculosis HIV-positive persons Isoniazid Streptomycin Rifampin Patients keyword: HIV Peru (source: DeCS BIREME) Mycobacterium tuberculosis Perú (fuente: DeCS BIREME) Resistencia a drogas VIH ab: Objective: To determine resistance rates to first-line antituberculous drugs in clinical samples from patients co-infected with the human immunodeficiency virus (HIV) and M. tuberculosis (TB) in five hospitals in Lima between 1998-2000. Materials and methods: A descriptive study including samples sent for culturing Mycobacterium tuberculosis in patients co-infected with HIV-TB. Susceptibility tests for isoniazid (H), streptomycin (S), ethambutol (E), and rifampin (R) were performed using the proportion method and Wayne's method for pyrazinamide (Z). Results: Out of 523 samples, 78,2% were from male patients, and 72,7% were from naive patients. Overall primary resistance and multidrug-resistance (MDR) rates were 55,8% and 32,1%, respectively; and overall acquired resistance and MDR rates were 93,0% and 74,8%, respectively. Primary resistance rates were: H, 42,1%; R, 35,0%; S, 35,3%; E, 19.0%, and Z, 24,5%, respectively; and acquired resistance rates were: h, 85,3%; R, 78,3%; S, 64,4%; E, 42,0%; and Z, 46,2%. Conclusion: There are high resistance rates to antituberculous drugs and MDR TB in patients co-infected with HIV and TB in Lima hospitals. Objetivos: Determinar los niveles de resistencia a drogas antituberculosas de primera línea en muestras clínicas de pacientes con coinfección por el virus de la inmunodeficiencia humana y tuberculosis (VIH-TB) en cinco hospitales de Lima en el periodo 1998-2000. Materiales y métodos: Estudio descriptivo que incluyó las muestras de cultivos de Mycobacterium tuberculosis de pacientes con coinfección VIH-TB, a los que se realizó las pruebas de sensibilidad por el método de las proporciones para isoniacida (H), estreptomicina (S), etambutol (E) y rifampicina (R), y el método de Wayne para pirazinamida (H). Resultados: De 523 muestras de pacientes incluidos, 78,2% correspondieron a varones, 72,7% fueron de pacientes sin antecedentes de tratamiento previo. Los valores de resistencia global primaria y multidrogorresistencia (MDR) primaria fueron 55,8% y 32,1%, respectivamente; en tanto que los valores de resistencia global adquirida y MDR adquirida fueron 93,0% y 74,8%. La resistencia primaria por drogas fue H (42,1%), R (35,0%), S (35,3%), E (19,0%) y Z (24,5%) respectivamente; y la resistencia adquirida por drogas fueron H (85,3%), R (78,3%), S (64,4%), E (42,0%) y Z (46,2%). Conclusión: Los niveles resistencia a drogas antituberculosas y la MDR en pacientes con coinfección VIH-TB provenientes de hospitales de Lima son elevados. pubtype: Academic Journal doctype: Article src: R language: Spanish refInfo: copyright: @attributes: flag: Y custom: Copyright of Revista Peruana de Medicina Experimental y Salud Pública is the property of Instituto Nacional de Salud (Peru) and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. item: Revista Peruana de Medicina Experimental y Salud Pública holder: Instituto Nacional de Salud (Peru) dt: @attributes: year: 2006 holdings: @attributes: islocal: N |
|---|